RenovoRx forms medical advisory board for RenovoCath device

RenovoRx Inc. (NASDAQ: RNXT) announced the establishment of a medical advisory board for its RenovoCath drug-delivery device. The board comprises six interventional radiology experts from medical institutions across the United States.

The advisory board will provide clinical insights to advance the company's TAMP therapy platform and support ongoing clinical and market strategies. Members will also offer feedback on potential investigator-initiated trials and assist the sales and marketing team in bringing RenovoCath to market as a standalone device.

The board includes Dr. Nadine Abi-Jaoudeh from UCI Health, Dr. Mustafa Al-Roubaie from Moffitt Cancer Center, Dr. Khashayar Farsad from Oregon Health and Science University, Dr. Ripal Gandhi from Baptist Health South Florida, Dr. Paula Marie Novelli from University of Pittsburgh Medical Center, and Dr. Jonathan Kessler from City of Hope Comprehensive Cancer Center.

RenovoCath is an FDA-cleared device intended for blood flow isolation and fluid delivery to select sites in the peripheral vascular system. The device is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx reported approximately $900,000 in revenue from RenovoCath sales for the first nine months of 2025. The company received its first commercial purchase orders for the device in December 2024.

The company is currently conducting a Phase III trial evaluating intra-arterial gemcitabine delivery in locally advanced pancreatic cancer using the RenovoCath device. RenovoCath with gemcitabine has received Orphan Drug Designation for pancreatic cancer and bile duct cancer.

You May Also Be Interested In

• Zai Lab and argenx report Phase 3 trial win for myositis drug
• HIVE's BUZZ HPC signs $350M five-year AI cloud services deal
• Centene names new CFO as Drew Asher plans to retire